Purity

Anti-CTLA-4 / CD152 Reference Antibody (ipilimumab) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.

SEC-HPLC

The purity of Anti-CTLA-4 / CD152 Reference Antibody (ipilimumab) is 99.37%, determined by SEC-HPLC.

FACS

Human CTLA-4 & Human PD-1 CHO-K cells were stained with Anti-CTLA-4 / CD152 Reference Antibody (ipilimumab) and negative control protein respectively, washed and then followed by PE and analyzed with FACS, EC50=0.2270 ug/mL.

Research in vivo

Ipilimumab inhibited the tumor growth of MC38 on huCTLA-4 mice. The result showed significant anti-tumor effects, with an tumor inhibition rate (TGI) of 99.3% at 0.88 mpk at D37.

-25~-15℃保存，有效期1年。